Literature DB >> 16643860

Relevance of astrocytic activation to reductions of astrocytic GABAA receptors.

Narito Tateishi1, Taiji Shimoda, Jun-ichiro Manako, Seishi Katsumata, Rika Shinagawa, Hiroyuki Ohno.   

Abstract

Although astrocytes express gamma-aminobutyric acid subtype-A (GABAA) receptors in the mature brain, GABAA receptor expression in a cultivation state remains controversial. In this study, we investigated the alteration of astrocytic GABAA receptor expression in in vitro and in vivo studies to elucidate the relevance of astrocytic activation to reductions of astrocytic GABAA receptors. The GABA-evoked Cl- current (GABAA response) in cultured astrocytes was determined by recording in the whole-cell mode using a conventional patch-clamp technique under voltage-clamp conditions. The respective amplitudes of GABAA responses on days in vitro 1, 3-5, 7-10, and 12-15 were 1019+/-97, 512+/-76, 84+/-21, and 22+/-9 pA, respectively, suggesting that the GABAA response subsequently diminished with in vitro aging. In immunohistochemical and biochemical analyses, the expression of GABAA receptor beta-subunit decreased, whereas expressions of glial fibrillary acidic protein (GFAP) and S100B, hallmarks of astrocytic activation, increased dramatically in the cultured astrocytes with in vitro aging. With the use of [3H]SR95531, a GABAA-specific ligand, at 24 h after transient focal ischemia, binding was significantly reduced in the astrocytic fractions without affecting the synaptosomal fractions, and decreases in the mRNA expression level of GABAA receptor beta-subunits were concurrently observed. Interestingly, the loss of GABAA response in cultured astrocytes was mitigated by co-culturing with neurons or treatments with monoclonal S100B antibodies. These results indicate that astrocytic GABAA receptors are reduced with in vitro aging and cerebral ischemia, presumably through the overproduction of S100B in activated astrocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643860     DOI: 10.1016/j.brainres.2006.02.139

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2018-10-06       Impact factor: 8.739

Review 2.  Astrocytes: GABAceptive and GABAergic Cells in the Brain.

Authors:  Jianhui Liu; Xuanran Feng; Yi Wang; Xiaohuan Xia; Jialin C Zheng
Journal:  Front Cell Neurosci       Date:  2022-06-10       Impact factor: 6.147

3.  Neural stem/progenitor cells derived from the embryonic dorsal telencephalon of D6/GFP mice differentiate primarily into neurons after transplantation into a cortical lesion.

Authors:  Iva Prajerova; Pavel Honsa; Alexandr Chvatal; Miroslava Anderova
Journal:  Cell Mol Neurobiol       Date:  2009-08-26       Impact factor: 5.046

4.  Midazolam suppresses interleukin-1β-induced interleukin-6 release from rat glial cells.

Authors:  Kumiko Tanabe; Osamu Kozawa; Hiroki Iida
Journal:  J Neuroinflammation       Date:  2011-06-17       Impact factor: 8.322

5.  Amantadine Combines Astroglial System Xc- Activation with Glutamate/NMDA Receptor Inhibition.

Authors:  Tomosuke Nakano; Toshiki Hasegawa; Dai Suzuki; Eishi Motomura; Motohiro Okada
Journal:  Biomolecules       Date:  2019-05-17

6.  Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>.

Authors:  Motohiro Okada; Kouji Fukuyama; Yasuhiro Kawano; Takashi Shiroyama; Yuto Ueda
Journal:  Pharmacol Res Perspect       Date:  2019-01-07

7.  Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.

Authors:  Laurence Desrues; Thomas Lefebvre; Céline Lecointre; Marie-Thérèse Schouft; Jérôme Leprince; Vincent Compère; Fabrice Morin; François Proust; Pierrick Gandolfo; Marie-Christine Tonon; Hélène Castel
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.